Neuronetics is trading 5.7% down now at $2.55 on November 5, with broad-market selling the likeliest backdrop, though the evidence does not establish a direct cause. - The stock advanced strongly the previous session after its November 4 earnings report, which showed $42.0 million in revenue, a narrower loss, and improved margin guidance; the results do not point to worsening company performance. - Major U.S. indexes are lower, while healthcare sector strength offers a counterpoint.